Nina D. Wagner‐Johnston

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Ajay K. Gopal, Brad S. Kahl, Sven de Vos et al. · New England Journal of Medicine · 2014 · 1K citations · Full text

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update

Charles L. Loprinzi, Christina Lacchetti, Jonathan Bleeker et al. · Journal of Clinical Oncology · 2020 · 963 citations · Full text

Cancer-Related Fatigue, Version 2.2015

Ann M. Berger, Kathi Mooney, Amy Alvarez-Perez et al. · Journal of the National Comprehensive Cancer Network · 2015 · 896 citations · Full text

Palliative Care, Fatigue Management, Medicine +10

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown, John C. Byrd, Steven Coutré et al. · Blood · 2014 · 583 citations · Full text

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 528 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8